Skip to main content
. 2003 Oct 24;2(Suppl 1):S9. doi: 10.1186/1475-2883-2-S1-S9

Figure 4.

Figure 4

Estimated rates of lifetime blindness (per 1000 population) and of death and chronic disability from L. loa encephalopathy, under conditions of 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40. Data are shown for two levels of loiasis co-endemicity, both with highly endemic onchocerciasis. Similar patterns are observed in areas of low onchocerciasis endemicity (data not shown).